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Figure 1. A) Disease free survival by pretransplant MRD status. B) Disease free survival by pretransplant MRD status in patients receiving high-dose TBI (1320 CGy),
cyclophosphamide and ﬂudarabine. C) Disease free survival by pretransplant MRD status in patients receiving treosulfan, ﬂudarabine, and a single fraction of 200CGy
TBI.
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differences were observed in patients receiving high-dose
TBI [29% vs. 12% (p¼0.10)]. Incidence of non-relapse
mortality was 15% (95% CI: 4-34) and 19% (95%CI: 10-31)
for MRDpos and MRDneg patients, respectively (p¼0.81).
Conclusion: Herein we demonstrate that the presence of
pre-transplant MRD after myeloablative CBT is associated
overall with adverse outcomes. However, the presence of
pre-transplant MRD impacted outcomes less if the patient
received a high-dose TBI-based preparative regimen. Our
study suggests furthering extending the use of CBT with
high-dose TBI in AML MRDpos patients.54
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Background: RIC regimens are reported to be associated
with equivalent outcome compared to ablative regimens
(MAC) but it is unknown if there are any outcome differences
after mismatched (MM) unrelated donor (URD) allo-SCT. We
hypothesized that, the historically higher relapse rate after
RIC compared to MAC can be abrogated by potent GVL effect
using MM URD.
Methods: Patients (pts) who underwent MAC or RIC MM
URD transplant from 2000-12 were included in the study. All
had donors with available information on HLA MM at one or
two loci (9/10 or 8/10). Regimens were classiﬁed as MAC or
RIC based on EBMT criteria. The Kaplan-Meier estimator, the
cumulative incidence function and Cox proportional hazards
regression models were used where appropriate.
Results: 1041 pts receiving MAC compared with 883 RIC
after MM-URD allo-SCT. Among the MAC, 872 (83.8%) were
9/10 and 169 (16.2%) 8/10 matched and in RIC cohort 754
(85.4%) were 9/10 and 129 (14.6%) were 8/10 matched.
Median follow up for MAC and RIC group was 27 and 23
months respectively. MAC recipients were signiﬁcantly
younger (median age 43 vs 57 year), 70% pts were <50 year
age in MAC vs only 30% in RIC group (p¼0.0001).
Signiﬁcantly higher numbers of pts had sAML (13 vs 10%,
p¼0.04) and KPS<90% (30 vs 25%, p¼0.02) in the RIC group.
There were no signiﬁcant differences in distributions of
advanced disease and poor risk cytogenetic among regimens.
Commonly used MAC regimens were TBI based (n¼369),
BuCy (354) and FluBu (143); and in the RIC group regimens
were low dose TBI based (n¼275), BuFlu (312) and FluMel
(178). The MAC group had more frequently marrow as the
stem cell source (20 vs 9%; p<0.0001). Percentages of
engraftment and grade II-IV aGVHD were not different
between the groups. The incidence of cGVHD was higher
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difference between MAC vs RIC for OS, LFS, RI and NRM
(Figure 1).
The analyses were performed separately for pts <50 and
50 year group. Among older cohorts (age 50), there was a
signiﬁcant advantage of RIC regimen with higher OS (44.6 vs
37.1%; p¼0.01), LFS (40.3 vs 34.3%; p¼0.03), decreased NRM
(29.6% vs 35.8%; p¼0.05), but no differences in RI (p¼0.95). A
higher cumulative incidence of cGVHD was seen after RIC
(37.6 vs 24.3%; p¼0.0009). Among younger cohort (age<50),
MAC showed no differences in OS, NRM and cGVHD
compared to the RIC group.
In multivariate analysis (age 50), higher OS (HR 0.78;
p¼0.01), LFS (HR 0.82; p¼0.05), and decreased NRM (HR
0.73; p¼0.03) were seen after RIC. RI (HR 0.91; p¼0.51) and
cGVHD (HR 1.31; p¼0.11) were, however, not signiﬁcantly
different. Pts<50 years old showed no differences in OS, LFS,
RI, NRM, and cGVHD between MAC or RIC group.
Conclusion: Our study shows no signiﬁcant outcome
difference between RIC and MAC regimens after MM URD
allo-SCT in pts younger than 50 years. Furthermore, data
support superiority of RIC regimen in older adults receiving
transplant from MM URD.IMMUNE RECONSTITUTION55
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